Ayala Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced participation in two upcoming investor conferences: the H.C. Wainwright & Co. 22nd Annual Global Healthcare Conference on September 15, 2020 at 12:30 PM ET, and the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020 at 1:40 PM ET. Live webcasts can be accessed on Ayala's website, with archived replays available for 90 days. The company focuses on developing small molecule therapeutics for rare and aggressive cancers, with lead candidate AL101 currently in Phase 2 clinical trials.

REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Ayala management will present at two upcoming investor conferences:

• H.C. Wainwright & Co. 22^nd Annual Global Healthcare Conference: Tuesday, September 15, 2020 at 12:30 pm ET.
• Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit: Monday, September 21, 2020 at 1:40 pm ET.

A live webcast of each presentation may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala’s lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

What upcoming investor conferences will Ayala Pharmaceuticals present at?

Ayala Pharmaceuticals will present at the H.C. Wainwright & Co. 22nd Annual Global Healthcare Conference on September 15, 2020, and the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020.

How can I watch Ayala Pharmaceuticals' conference presentations?

Live webcasts of Ayala Pharmaceuticals' presentations can be accessed on the Events & Presentations section of their website, with archived replays available for 90 days.

What is the focus of Ayala Pharmaceuticals in oncology?

Ayala Pharmaceuticals is focused on developing small molecule therapeutics for patients with rare and aggressive cancers, targeting genetically defined patient populations.

What are the lead product candidates of Ayala Pharmaceuticals?

Ayala's lead product candidate is AL101, which targets aberrant activation of the Notch pathway and is currently in a Phase 2 clinical trial for patients with Adenoid Cystic Carcinoma.

What designations has AL101 received from the U.S. FDA?

AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA.